JP2019525897A5 - - Google Patents

Download PDF

Info

Publication number
JP2019525897A5
JP2019525897A5 JP2018563925A JP2018563925A JP2019525897A5 JP 2019525897 A5 JP2019525897 A5 JP 2019525897A5 JP 2018563925 A JP2018563925 A JP 2018563925A JP 2018563925 A JP2018563925 A JP 2018563925A JP 2019525897 A5 JP2019525897 A5 JP 2019525897A5
Authority
JP
Japan
Prior art keywords
immunoglobulin
residue
amino acid
item
binding portion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018563925A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019525897A (ja
JP7041077B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2017/021672 external-priority patent/WO2017213267A1/en
Publication of JP2019525897A publication Critical patent/JP2019525897A/ja
Publication of JP2019525897A5 publication Critical patent/JP2019525897A5/ja
Application granted granted Critical
Publication of JP7041077B2 publication Critical patent/JP7041077B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018563925A 2016-06-10 2017-06-12 リジン結合体化免疫グロブリン Active JP7041077B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662348410P 2016-06-10 2016-06-10
US62/348,410 2016-06-10
PCT/JP2017/021672 WO2017213267A1 (en) 2016-06-10 2017-06-12 Lysine conjugated immunoglobulins

Publications (3)

Publication Number Publication Date
JP2019525897A JP2019525897A (ja) 2019-09-12
JP2019525897A5 true JP2019525897A5 (https=) 2020-07-16
JP7041077B2 JP7041077B2 (ja) 2022-03-23

Family

ID=59315675

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018563925A Active JP7041077B2 (ja) 2016-06-10 2017-06-12 リジン結合体化免疫グロブリン

Country Status (21)

Country Link
US (2) US10941431B2 (https=)
EP (1) EP3468614A1 (https=)
JP (1) JP7041077B2 (https=)
KR (1) KR102538866B1 (https=)
CN (1) CN109475642B (https=)
AU (1) AU2017279352B2 (https=)
BR (1) BR112018075253A2 (https=)
CA (1) CA3026991A1 (https=)
CL (1) CL2021003383A1 (https=)
CO (1) CO2018013314A2 (https=)
IL (1) IL263329B (https=)
JO (1) JOP20180118A1 (https=)
MX (1) MX419566B (https=)
MY (1) MY202858A (https=)
NZ (1) NZ748605A (https=)
PE (1) PE20190340A1 (https=)
PH (1) PH12018502594A1 (https=)
RU (2) RU2762939C2 (https=)
SG (1) SG11201810470XA (https=)
UA (1) UA126799C2 (https=)
WO (1) WO2017213267A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11135304B2 (en) 2015-12-18 2021-10-05 Eisai R&D Management Co., Ltd. C-terminal lysine conjugated immunoglobulins
UA126799C2 (uk) 2016-06-10 2023-02-08 ЕЙСАЙ Ар ЕНД Ді МЕНЕДЖМЕНТ КО., ЛТД. Кон'югований імуноглобулін
US20210054049A1 (en) * 2019-05-09 2021-02-25 Merus N.V. Variant domains for multimerizing proteins and separation thereof
GB201907093D0 (en) * 2019-05-20 2019-07-03 Ucl Business Plc Antibody functionalisation
CN115335406B (zh) * 2020-02-12 2026-01-30 伊莱利利公司 抗体或抗原-结合片段的结晶
EP4126929A1 (en) * 2020-03-25 2023-02-08 Eli Lilly and Company Multispecific binding proteins and methods of developing the same
WO2021234593A1 (en) 2020-05-20 2021-11-25 Janssen Biotech, Inc. Methods for site specific conjugation of proteins containing glycosylated fc domains
WO2022067076A1 (en) * 2020-09-25 2022-03-31 Epivax, Inc. Retro-inverso regulatory t cell epitopes
MX2024002476A (es) * 2021-08-27 2024-05-20 Janssen Biotech Inc Anticuerpos anti-psma y usos de estos.
CN115947830B (zh) * 2022-12-27 2023-09-12 优洛生物(上海)有限公司 一种经改造的抗体、其制备方法及其用途
WO2024182569A2 (en) 2023-02-28 2024-09-06 Eisai R&D Management Co., Ltd. Anti-psma antibodies, conjugates, and methods of use
WO2024211135A2 (en) * 2023-04-07 2024-10-10 Regeneron Pharmaceuticals, Inc. Characterization of crosslinking sites in antibody-drug conjugates
WO2025020905A1 (zh) * 2023-07-26 2025-01-30 菲鹏生物股份有限公司 抗体和抗体缀合物及其用途
WO2025199464A1 (en) 2024-03-22 2025-09-25 Eisai R&D Management Co., Ltd. Anti-trop2 antibody-drug conjugates and methods of use
CN120779021A (zh) * 2024-04-08 2025-10-14 菲鹏生物股份有限公司 抗体缀合物及其用途
WO2026044149A2 (en) 2024-08-21 2026-02-26 Eisai R&D Management Co., Ltd. Synthesis of drug-linker combinations for antibody-drug conjugates
WO2026044039A2 (en) 2024-08-21 2026-02-26 Eisai R&D Management Co., Ltd. Anti-cd73 antibodies, conjugates, and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
EP2033662B1 (en) * 2004-01-21 2012-10-17 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
US9676871B2 (en) * 2010-11-05 2017-06-13 Pfizer Inc. Engineered polypeptide conjugates and methods for making thereof using transglutaminase
WO2013176516A1 (ko) 2012-05-24 2013-11-28 한화케미칼 주식회사 트랜스글루타미나아제를 이용하여 제조한 항체-약물 결합체 및 이의 용도
US10036010B2 (en) 2012-11-09 2018-07-31 Innate Pharma Recognition tags for TGase-mediated conjugation
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
JP6744212B2 (ja) * 2013-06-21 2020-08-19 イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. ポリペプチドの酵素的結合
EP3019515B1 (en) * 2013-07-11 2019-08-21 Novartis AG Lysine-specific chemoenzymatic protein modifications using microbial transglutaminase
EP3027224B1 (en) * 2013-07-31 2020-06-03 Rinat Neuroscience Corp. Engineered polypeptide conjugates using transglutaminase
SI3134127T1 (sl) 2014-04-25 2020-06-30 Rinat Neuroscience Corp. Konjugati zdravil s protitelesi z visoko stopnjo zdravila
US11135304B2 (en) 2015-12-18 2021-10-05 Eisai R&D Management Co., Ltd. C-terminal lysine conjugated immunoglobulins
UA126799C2 (uk) 2016-06-10 2023-02-08 ЕЙСАЙ Ар ЕНД Ді МЕНЕДЖМЕНТ КО., ЛТД. Кон'югований імуноглобулін

Similar Documents

Publication Publication Date Title
JP2019525897A5 (https=)
JP2019502684A5 (https=)
JP7360377B2 (ja) アントラサイクリン誘導体を含む、結合タンパク質薬物複合体(Binding protein drug conjugates)
JP7133611B2 (ja) 高いインビボ忍容性を有するアントラサイクリン系の抗体薬物複合体
ES2277344T3 (es) Purificacion de anticuerpos mediante cromatografia de interaccion hidrofobica a ph bajo.
US20220088212A1 (en) C-terminal lysine conjugated immunoglobulins
ES2549077T3 (es) Espectrometría de masas de conjugados de anticuerpos
JP6105477B2 (ja) 操作されたポリペプチドコンジュゲートおよびトランスグルタミナーゼを用いてそれを作製する方法
CN109475642B (zh) 赖氨酸缀合的免疫球蛋白
JP6585600B2 (ja) C末端軽鎖ポリペプチド伸長を含有する抗体、ならびにその複合体及びその使用方法
BR112015023589B1 (pt) Método para a produção de um conjugado de imunoligante/carga útil
JP7514836B2 (ja) トランスグルタミナーゼによるコンジュゲーションのための改変抗体、ならびにそのコンジュゲート、方法および用途
JP2018520092A5 (https=)
JP7339291B2 (ja) シクロホスファミド及びイホスファミドのイムノアッセイ用の免疫原及びアッセイ接合体として用いるシクロホスファミド類似体
CN110799537A (zh) 抗pd-1抗体及其制备和使用方法
EP3999544A1 (en) Polypeptide complex for conjugation and use thereof
CN108601848A (zh) 用于制备细胞结合剂-细胞毒性剂缀合物的有效方法
AU2019386945B2 (en) Antibody comprising a glutamine-containing light chain C-terminal extension, conjugates thereof, and methods and uses
TWI591176B (zh) 抗liv-1之人化抗體類及彼等於治療癌症上之用途
CA3008645C (en) C-terminal lysine conjugated immunoglobulins
KR20250045545A (ko) 항체-킬레이터 콘쥬게이트
JP2024500921A (ja) 開環チオスクシンイミド基、オリゴペプチドフラグメント及びキラル部分を含む新規異性化合物
NZ751907B2 (en) Anti-muc16 (mucin 16) antibodies
NZ751907A (en) Anti-muc16 (mucin 16) antibodies
BR112016018005B1 (pt) Conjugados anticorpo-droga e imunotoxinas